Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity

By Henry C. Quevedo, K. Hatzistergos, Behzad N. Oskouei, Gary S. Feigenbaum, Jose E Rodriguez, David Valdes, P. Pattany, J. Zambrano, Qinghua Hu, I. Mcniece and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2009

617 citations recorded by the source corpus.

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/e4ccf1cd501e346f7e6a94ca108ebe88138c4f6f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Fishman
2. G. Gerstenblith
3. Darcy L DiFede Velazquez
4. J. Hare
5. J. Zambrano
6. P. Ruiz
7. A. Mendizabal
8. E. Ghersin

Citations in the corpus

• Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy (2012, background): “Mesenchymal stem cells engraft and persist for several months in myocardium when delivered by TESI(31-33,42) and exert a range of effects, including reducing tissue fibrosis, differentiating into small and large blood vessels (vasculogenesis), participating in myogenesis, and releasing paracrine fac”